CORRESP Filing
Annovis Bio, Inc.
Date: Sept. 19, 2025 · CIK: 0001477845 · Accession: 0001104659-25-091784
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39202
Referenced dates: September 4, 2025
Letter
Via EDGAR Ms. Jenn Do and Ms. Vanessa Robertson U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549
Re: Annovis Bio, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 21, 2025 File No. 001-39202
Dear Ms. Do and Ms. Robertson:
Annovis Bio, Inc. (the "Company") is in receipt of the Staff's letter dated September 4, 2025 (the "Staff's Letter") regarding the Company's Annual Report on Form 10-K (the "Form 10-K"). Based on my telephone conversation with Ms. Do on September 15, 2025, the Staff requested, and the Company hereby agrees that, in future filings, it will provide narrative disclosure, on a going-forward basis only (no prior period comparison) regarding the breakdown of research and development expenses between the Alzheimer's study and the Parkinson's study. In addition, the filings will continue to show the breakdown as reported in previous filings, Exhibit A.
Please contact me at (610) 880-8485 or by email at maccecchini@annovisbio.com if you have any additional questions.
Sincerely,
Maria Maccecchini
Show Raw Text
CORRESP 1 filename1.htm Via EDGAR September 19, 2025 Ms. Jenn Do and Ms. Vanessa Robertson U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Re: Annovis Bio, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 21, 2025 File No. 001-39202 Dear Ms. Do and Ms. Robertson: Annovis Bio, Inc. (the "Company") is in receipt of the Staff's letter dated September 4, 2025 (the "Staff's Letter") regarding the Company's Annual Report on Form 10-K (the "Form 10-K"). Based on my telephone conversation with Ms. Do on September 15, 2025, the Staff requested, and the Company hereby agrees that, in future filings, it will provide narrative disclosure, on a going-forward basis only (no prior period comparison) regarding the breakdown of research and development expenses between the Alzheimer's study and the Parkinson's study. In addition, the filings will continue to show the breakdown as reported in previous filings, Exhibit A. Please contact me at (610) 880-8485 or by email at maccecchini@annovisbio.com if you have any additional questions. Sincerely, Maria Maccecchini President and Chief Executive Officer EXHIBIT A Table from Annovis Bio 2024 10-K Year Ended December 31, 2024 2023 Change (in thousands) Operating expenses: Research and development $ 19,995 $ 38,791 $ (18,796 ) General and administrative 6,699 6,244 455 Total operating expenses 26,694 45,035 (18,341 ) Other income (expense): Interest income 332 668 (336 ) Other financing costs (1,853 ) - (1,853 ) Change in fair value of warrants 3,626 (11,837 ) 15,463 Other income (expense), net 2,105 (11,169 ) 13,274 Net loss $ 24,589 $ 56,204 $ (31,615 ) 2